Teleflex (NYSE:TFX) Getting Somewhat Favorable Press Coverage, Analysis Shows
Headlines about Teleflex (NYSE:TFX) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teleflex earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the medical technology company an impact score of 46.3393814151116 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern’s scoring:
- Insider Selling: Teleflex Incorporated (TFX) Director Sells 2,500 Shares of Stock (americanbankingnews.com)
- Teleflex to Present at Needham & Company’s 17th Annual Healthcare Conference (finance.yahoo.com)
- Teleflex (TFX) Cut to Hold at ValuEngine (americanbankingnews.com)
- Teleflex Incorporated (TFX) Expected to Announce Quarterly Sales of $568.96 Million (americanbankingnews.com)
- Teleflex (TFX) Presents At Raymond James 39th Annual Institutional Investors Conference – Slideshow (seekingalpha.com)
A number of equities research analysts have recently issued reports on the stock. Leerink Swann reaffirmed a “buy” rating and set a $321.00 target price (up previously from $307.00) on shares of Teleflex in a report on Tuesday, January 30th. Stephens reaffirmed a “buy” rating and set a $300.00 target price on shares of Teleflex in a report on Thursday, January 18th. TheStreet lowered shares of Teleflex from an “a-” rating to a “c+” rating in a report on Monday. ValuEngine lowered shares of Teleflex from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Finally, Deutsche Bank lowered shares of Teleflex from a “buy” rating to a “hold” rating and set a $251.00 target price for the company. in a report on Tuesday, November 14th. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $281.56.
Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $2.44 earnings per share for the quarter, beating the consensus estimate of $2.40 by $0.04. The firm had revenue of $595.10 million for the quarter, compared to analysts’ expectations of $601.17 million. Teleflex had a net margin of 7.11% and a return on equity of 16.46%. The company’s revenue was up 15.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.13 EPS. analysts expect that Teleflex will post 9.68 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Friday, March 2nd will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, March 1st. This represents a $1.36 annualized dividend and a dividend yield of 0.51%. Teleflex’s payout ratio is 41.59%.
In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $248.96, for a total value of $49,792.00. Following the transaction, the director now owns 8,080 shares of the company’s stock, valued at $2,011,596.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP John Deren sold 1,359 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $255.67, for a total transaction of $347,455.53. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,259 shares of company stock worth $3,760,536. Corporate insiders own 2.39% of the company’s stock.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.